Analysts Set Telix Pharmaceuticals Limited (NASDAQ:TLX) PT at $21.50

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have been assigned a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $21.50.

Several equities research analysts have commented on TLX shares. HC Wainwright dropped their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, September 10th. Citigroup started coverage on Telix Pharmaceuticals in a research note on Thursday. They set a “buy” rating and a $22.00 price target for the company. William Blair restated an “outperform” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Wedbush reiterated an “outperform” rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Pier Capital LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at approximately $3,037,000. Russell Investments Group Ltd. acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at approximately $975,000. Jane Street Group LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at approximately $564,000. ABC Arbitrage SA acquired a new stake in Telix Pharmaceuticals during the 1st quarter valued at approximately $451,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at approximately $297,000.

Telix Pharmaceuticals Price Performance

Shares of NASDAQ:TLX opened at $9.98 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.66 and a current ratio of 2.78. The business has a 50-day moving average of $11.88 and a two-hundred day moving average of $15.12. Telix Pharmaceuticals has a 12 month low of $8.93 and a 12 month high of $30.36.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.